mTor Inhibitors for the Treatment of Endometriosis

The rational of the study is based on the evidence of the pivotal role of mTOR in angiogenesis and growth of endometriotic implants 4 . The results of the therapy are in line with a previous study performed on the animal model 5 , in which Leconte et al. found that also the administration of temsirolimus (intraperitoneal 3 mg/kg), another mTor inhibitor, for 2 weeks led to significant decreases in endometriosis implants growth. Although the authors should be congratulated for their laboratory findings, we would like to raise some concerns on the administration of mTor inhibitors, and in particular everolimus, in the clinical treatment of endometriosis. Everolimus is approved by Food and Drug Administration (FDA) for the treatment of advanced tumors, such as advanced kidney cancer, progressive or metastatic pancreatic or gastrointestinal neuroendocrine tumors, and it is currently being also evaluated in gynecological cancers. Moreover, its use is indicated for immunosuppression after solid organ transplant 6 . Although in oncologic setting it has been reported that patients with specific mutations (i.e. PIK3A, PTEN) tend to have higher benefit receiving mTor pathway inhibitors, a first non-negligible problem is that there are no validated predictive biomarkers for patientsʼ selection and for monitoring drug efficacy 7 . A second concern is related to the fact that in the experiment endometriotic implants were surgically induced only in peritoneum of rats, and not in other localizations. Thus, it appears unlikely that drugs acting on angiogenesis-related pathways, such as mTor, may treat the symptoms caused by large nodules of deep infiltrating endometriosis (DIE), which are mainly composed of fibromuscular tissue, and may have already been present for some years. More importantly, drugs targeting mTor pathway may cause adverse effects 8 , including a large variety of metabolic, hematological, respiratory, renal and dermatological toxicities. These sometime serious side effects explain the notable rate of drug discontinuation in clinical trials for advanced cancer. Although some of them, such as oral stomatitis (30 – 60% of patients) or pneumonitis, seem to increase with the dosage of the drug, the majority are idiosyncratic and unpredictable, and may also occur from days to years after the beginning of the therapy. These adverse effects may be tolerable in oncological therapy, where the primary endpoints are disease-free survival and overall survival, but it appears difficult to accept them in young women with endometriosis where the goal is improving the quality of life. In fact, endometriosis is a chronic benign disease that requires a long-term therapy combining clinical efficacy (preventing recurrence, controlling pain symptoms) with acceptable costs and toxicity. Given this background, it seems unlikely that everolimus may have a relevant role in the future treatment of women with endometriosis.